{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&AnswerDate=2018-11-19&min-ddpModified.=2018-11-19T17%3A24%3A03.526Z", "definition" : "https://eldaddp.azurewebsites.net/meta/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&AnswerDate=2018-11-19&min-ddpModified.=2018-11-19T17%3A24%3A03.526Z", "extendedMetadataVersion" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&AnswerDate=2018-11-19&_metadata=all&min-ddpModified.=2018-11-19T17%3A24%3A03.526Z", "first" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=0&AnswerDate=2018-11-19&min-ddpModified.=2018-11-19T17%3A24%3A03.526Z", "hasPart" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&AnswerDate=2018-11-19&min-ddpModified.=2018-11-19T17%3A24%3A03.526Z", "isPartOf" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&AnswerDate=2018-11-19&min-ddpModified.=2018-11-19T17%3A24%3A03.526Z", "items" : [{"_about" : "http://data.parliament.uk/resources/1007757", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007757/answer", "answerText" : {"_value" : "
The United Kingdom\u2019s position on medicines regulation remains clear. We want to retain a close working partnership with the European Union to ensure that medicines remain available to UK patients in a safe and timely manner. We have been clear that this involves us making sure our regulators continue to work together, as they do with regulators internationally. As the Prime Minister has said, we intend to to explore with the EU the terms on which the UK could remain part the European Medicines Agency.<\/p>
<\/p>
Until we can be certain of the outcome of Brexit negotiations our duty as a responsible Government is to prepare for all eventualities, including \u2018no deal\u2019. On 23 August 2018, therefore, the Department wrote to all pharmaceutical companies that supply the United Kingdom with prescription only or pharmacy medicines from, or via, the European Union/European Economic Area, asking them to ensure they have a minimum of six weeks\u2019 additional supply in the UK, over and above their business as usual operational buffer stocks, by 29 March 2019 in the event of a no-deal scenario.<\/p>
<\/p>
Since then, we have received very good engagement from industry who share our aims of ensuring continuity of medicines supply for patients is maintained and able to cope with any potential delays at the border that may arise in the short term in the event of a no-deal Brexit.<\/p>
<\/p>
We understand that the medicine Keppra is important to many people in this country. However, the Department recognises that through its medicines supply contingency programme it is requesting sensitive commercial information from pharmaceutical companies. To reassure participating companies, we have committed to treating all information received confidentially, securely and to using it only for the purposes of the Department\u2019s programme. That means not introducing information about a company, specific medicine or their supply routes into the public domain.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T11:54:10.717Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Levetiracetam"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will make an assessment of the effect of the UK leaving the EU on the availability of Keppra for people with epilepsy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4648", "label" : {"_value" : "Biography information for Laura Smith"} } , "tablingMemberConstituency" : {"_value" : "Crewe and Nantwich"} , "tablingMemberPrinted" : [{"_value" : "Laura Smith"} ], "uin" : "191984"} , {"_about" : "http://data.parliament.uk/resources/1007767", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007767/answer", "answerText" : {"_value" : "
The National Institute for Health and Care Excellence (NICE) is currently developing technology appraisal guidance for the National Health Service on the use of Spinraza (nusinersen) for the treatment of spinal muscular atrophy (SMA).<\/p>
<\/p>
NICE is in discussion with Biogen (the company that manufactures Spinraza) to determine if there are any commercial flexibilities that could support the company in putting forward a cost-effective price in order for NICE to recommend use of the drug as a clinically and cost-effective use of NHS resources.<\/p>
<\/p>
NHS England has published an Interim Policy Statement determining the circumstances in which existing patients will be supported to access Spinraza through the Expanded Access Programme (EAP) scheme sponsored by Biogen. The policy statement enables existing patients with type 1 SMA to access Spinraza in advance of NICE\u2019s guidance, although the company has now withdrawn the EAP for newly diagnosed patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T15:13:09.58Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Nusinersen"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress NHS England, Biogen and NICE have made in discussions on a managed access agreement for the use of Spinraza for the treatment of spinal muscular dystrophy.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4249", "label" : {"_value" : "Biography information for Anne Marie Morris"} } , "tablingMemberConstituency" : {"_value" : "Newton Abbot"} , "tablingMemberPrinted" : [{"_value" : "Anne Marie Morris"} ], "uin" : "191928"} , {"_about" : "http://data.parliament.uk/resources/1007777", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007777/answer", "answerText" : {"_value" : "
The NHS Cancer Programme is working to improve access to cancer nurse specialists (CNSs) for all cancer patients when they need it, including those with secondary breast cancer.<\/p>
<\/p>
We are committed to rolling out the recovery package to every cancer patient by 2020. The recovery package is a set of four interventions designed to help patients and clinicians assess a patient\u2019s holistic needs, including physical and emotional needs, at appropriate time points through their cancer journey, as needs do change especially when a person is diagnosed with secondary cancer. A personalised care and support plan to meets these needs should be agreed, ensuring signposting and referral to the right support and care services is made, and also helping to empower patients to independently manage their own health, with advice and support.<\/p>
<\/p>
NHS England is committed to giving more patients access to a CNS or other specialist from diagnosis onwards to guide them through treatment options and ensure they receive appropriate information and support. In their first Cancer Workforce Plan, which was published in December 2017, Health Education England committed to supporting the expansion of CNSs by developing national competencies and a clear route into training. This will ensure that every patient has access to a CNS or other support worker by 2021.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T15:20:10.943Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Breast Cancer"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will introduce a secondary support package covering breast cancer care to include (a) access to a dedicated clinical nurse specialist, (b) an assessment of physical and emotional needs at (i) diagnosis and (ii) through treatment and referral and (c) signposting to tailored, specialist support services.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/478", "label" : {"_value" : "Biography information for Lord Field of Birkenhead"} } , "tablingMemberConstituency" : {"_value" : "Birkenhead"} , "tablingMemberPrinted" : [{"_value" : "Frank Field"} ], "uin" : "191871"} , {"_about" : "http://data.parliament.uk/resources/1007778", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007778/answer", "answerText" : {"_value" : "
In July 2018, the Government Equalities Office published a report titled \u2018Improving LGBT lives: Government action since 2010\u2019 which is available at the following link:<\/p>
<\/p>
Financial Year (FY) 2013/14<\/p><\/td> | FY 2014/15<\/p><\/td> | FY 2015/16<\/p><\/td> | FY 2016/17<\/p><\/td> | FY 2017/18<\/p><\/td> | Total<\/p><\/td><\/tr> |
69,386<\/p><\/td> | 993,419<\/p><\/td> | 1,107,936<\/p><\/td> | 1,392,344<\/p><\/td> | 1,393,003<\/p><\/td> | 4,956,090<\/p><\/td><\/tr><\/tbody><\/table>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4008", "label" : {"_value" : "Biography information for Dame Caroline Dinenage"} } , "answeringMemberConstituency" : {"_value" : "Gosport"} , "answeringMemberPrinted" : {"_value" : "Caroline Dinenage"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T12:14:05.067Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Parkinson's Disease: Research"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how much the National Institute of Health Research spent on research into mental health interventions for people with Parkinson\u2019s disease who have anxiety and/or depression in each of the five years up to and including 2017.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3957", "label" : {"_value" : "Biography information for Martin Vickers"} } , "tablingMemberConstituency" : {"_value" : "Cleethorpes"} , "tablingMemberPrinted" : [{"_value" : "Martin Vickers"} ], "uin" : "191901"} , {"_about" : "http://data.parliament.uk/resources/1007788", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007788/answer", "answerText" : {"_value" : " The information is not held in the format requested.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4067", "label" : {"_value" : "Biography information for Steve Brine"} } , "answeringMemberConstituency" : {"_value" : "Winchester"} , "answeringMemberPrinted" : {"_value" : "Steve Brine"} , "dateOfAnswer" : {"_value" : "2018-11-22", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-22T15:11:14.177Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Prescriptions: Fees and Charges"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, how many prescription items were dispensed for free in each exemption category in the last period for which figures are available.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/3957", "label" : {"_value" : "Biography information for Martin Vickers"} } , "tablingMemberConstituency" : {"_value" : "Cleethorpes"} , "tablingMemberPrinted" : [{"_value" : "Martin Vickers"} ], "uin" : "191902"} , {"_about" : "http://data.parliament.uk/resources/1007816", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1007816/answer", "answerText" : {"_value" : " The Independent Review of the Mental Health Act will report before the end of the year. The Government will consider its findings and respond in due course. The Review will make recommendations to Government for how it should improve the Act, including considering what changes might be needed to reduce the number of detentions under the Act, but the Review itself was not commissioned to have a direct influence on legislation or practice.<\/p> <\/p> We have therefore made no assessment on the effect of the Independent Review of the Mental Health Act on the rate of detentions under the Mental Health Act 1983.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4065", "label" : {"_value" : "Biography information for Dame Jackie Doyle-Price"} } , "answeringMemberConstituency" : {"_value" : "Thurrock"} , "answeringMemberPrinted" : {"_value" : "Jackie Doyle-Price"} , "dateOfAnswer" : {"_value" : "2018-11-23", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "191977"} , {"_value" : "192127"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2018-11-23T11:17:27.91Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2018-11-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Compulsorily Detained Psychiatric Patients: West Midlands"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the Independent Review of the Mental Health Act on the rate of detentions under the Mental Health Act 1983 in Birmingham and Solihull Clinical Commissioning Group.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4603", "label" : {"_value" : "Biography information for Preet Kaur Gill"} } , "tablingMemberConstituency" : {"_value" : "Birmingham, Edgbaston"} , "tablingMemberPrinted" : [{"_value" : "Preet Kaur Gill"} ], "uin" : "191976"} ], "itemsPerPage" : 10, "next" : "https://eldaddp.azurewebsites.net/answeredquestions.text?answeringDeptShortName=Health+and+Social+Care&_page=1&AnswerDate=2018-11-19&min-ddpModified.=2018-11-19T17%3A24%3A03.526Z", "page" : 0, "startIndex" : 1, "totalResults" : 51, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} } |